TFAP2C-mediated upregulation of TGFBR1 promotes lung tumorigenesis and epithelial–mesenchymal transition

Experimental and Molecular Medicine

Volumn 48, Issue 11, 2016, Pages

  Kim, Wanyeon ^a   Kim, Eungi ^a   Lee, Sungmin ^a   Kim, Daehoon ^a   Chun, Jahyun ^a   Park, Kang Hyun ^a   Youn, Hyesook ^b   Youn, Buhyun ^a  

^a Pusan National University   (South Korea)

^b Sejong University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN SERINE THREONINE KINASE; TFAP2C PROTEIN, HUMAN; TGF-BETA TYPE I RECEPTOR; TRANSCRIPTION FACTOR AP 2; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

AGED; ANIMAL; BAGG ALBINO MOUSE; CARCINOGENESIS; CELL LINE; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LUNG TUMOR; MALE; METABOLISM; MIDDLE AGED; NON SMALL CELL LUNG CANCER; NUDE MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TUMOR CELL LINE;

AGED; ANIMALS; CARCINOGENESIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE; CELL LINE, TUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR AP-2; TRANSCRIPTIONAL ACTIVATION;

EID: 85029441040     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.1038/EMM.2016.125     Document Type: Article

References (35)

1. Devarakonda S, Morgensztern D, Govindan R. Genomic alterations in lung adenocarcinoma. Lancet Oncol 2015; 16: e342–e351.
2. Janku F, Stewart DJ, Kurzrock R. Targeted therapy in non-small-cell lung cancer—is it becoming a reality? Nat Rev Clin Oncol 2010; 7: 401–414.
3. Komurov K, Tseng JT, Muller M, Seviour EG, Moss TJ, Yang L et al. The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer cells. Mol Syst Biol 2012; 8: 596.
4. Eckert D, Buhl S, Weber S, Jager R, Schorle H. The AP-2 family of transcription factors. Genome Biol 2005; 6: 246.
5. Hilger-Eversheim K, Moser M, Schorle H, Buettner R. Regulatory roles of AP-2 transcription factors in vertebrate development, apoptosis and cell-cycle control. Gene 2000; 260: 1–12.
6. Ailan H, Xiangwen X, Daolong R, Lu G, Xiaofeng D, Xi Q et al. Identification of target genes of transcription factor activator protein 2 gamma in breast cancer cells. BMC Cancer 2009; 9: 279.
7. Woodfield GW, Chen Y, Bair TB, Domann FE, Weigel RJ. Identification of primary gene targets of TFAP2C in hormone responsive breast carcinoma cells. Genes Chromosomes Cancer 2010; 49: 948–962.
8. Williamson JA, Bosher JM, Skinner A, Sheer D, Williams T, Hurst HC. Chromosomal mapping of the human and mouse homologues of two new members of the AP-2 family of transcription factors. Genomics 1996; 35: 262–264.
9. Massague J, Gomis RR. The logic of TGFbeta signaling. FEBS Lett 2006; 580: 2811–2820.
10. Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003; 113: 685–700.
11. Barrios-Rodiles M, Brown KR, Ozdamar B, Bose R, Liu Z, Donovan RS et al. High-throughput mapping of a dynamic signaling network in mammalian cells. Science 2005; 307: 1621–1625.
12. Vogelmann R, Nguyen-Tat MD, Giehl K, Adler G, Wedlich D, Menke A. TGFbeta-induced downregulation of E-cadherin-based cell-cell adhesion depends on PI3-kinase and PTEN. J Cell Sci 2005; 118: 4901–4912.
13. Mu Y, Gudey SK, Landstrom M. Non-Smad signaling pathways. Cell Tissue Res 2012; 347: 11–20.
14. Gomes LR, Terra LF, Wailemann RA, Labriola L, Sogayar MC. TGF-beta1 modulates the homeostasis between MMPs and MMP inhibitors through p38 MAPK and ERK1/2 in highly invasive breast cancer cells. BMC Cancer 2012; 12: 26.
15. Derynck R, Akhurst RJ, Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 2001; 29: 117–129.
16. Miyazono K. Transforming growth factor-beta signaling in epithelial– mesenchymal transition and progression of cancer. Proc Jpn Acad Ser B 2009; 85: 314–323.
17. Inman GJ. Switching TGFbeta from a tumor suppressor to a tumor promoter. Curr Opin Genet Dev 2011; 21: 93–99.
18. Kwon T, Youn H, Son B, Kim D, Seong KM, Park S et al. DANGER is involved in high glucose-induced radioresistance through inhibiting DAPK-mediated anoikis in non-small cell lung cancer. Oncotarget 2016; 7: 7193–7206.
19. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2( − Delta Delta C(T)) Method. Methods 2001; 25: 402–408.
20. Kim W, Youn H, Kwon T, Kang J, Kim E, Son B et al. PIM1 kinase inhibitors induce radiosensitization in non-small cell lung cancer cells. Pharmacol Res 2013; 70: 90–101.
21. Kang J, Kim W, Kwon T, Youn H, Kim JS, Youn B. Plasminogen activator inhibitor-1 enhances radioresistance and aggressiveness of non-small cell lung cancer cells. Oncotarget 2016; 7: 23961–23974.
22. Kim E, Youn H, Kwon T, Son B, Kang J, Yang HJ et al. PAK1 tyrosine phosphorylation is required to induce epithelial-mesenchymal transition and radioresistance in lung cancer cells. Cancer Res 2014; 74: 5520–5531.
23. Youn H, Son B, Kim W, Jun SY, Lee JS, Lee JM et al. Dissociation of MIF-rpS3 complex and sequential NF-kappaB activation is involved in IR-induced metastatic conversion of NSCLC. J Cell Biochem 2015; 116: 2504–2516.
24. Son B, Jun SY, Seo H, Youn H, Yang HJ, Kim W et al. Inhibitory effect of traditional oriental medicine-derived monoamine oxidase B inhibitor on radioresistance of non-small cell lung cancer. Sci Rep 2016; 6: 21986.
25. Kim W, Youn H, Kang C, Youn B. Inflammation-induced radioresistance is mediated by ROS-dependent inactivation of protein phosphatase 1 in non-small cell lung cancer cells. Apoptosis 2015; 20: 1242–1252.
26. Kim W, Kim E, Yang HJ, Kwon T, Han S, Lee S et al. Inhibition of hedgehog signalling attenuates UVB-induced skin photoageing. Exp Dermatol 2015; 24: 611–617.
27. Petty RD, Sutherland LA, Hunter EM, Cree IA. Comparison of MTT and ATP-based assays for the measurement of viable cell number. J Biolumin Chemilumin 1995; 10: 29–34.
28. Kang J, Kim E, Kim W, Seong KM, Youn H, Kim JW et al. Rhamnetin and cirsiliol induce radiosensitization and inhibition of epithelial-mesenchymal transition (EMT) by miR-34a-mediated suppression of Notch-1 expression in non-small cell lung cancer cell lines. J Biol Chem 2013; 288: 27343–27357.
29. Mortazavi F, Lu J, Phan R, Lewis M, Trinidad K, Aljilani A et al. Significance of KRAS/PAK1/Crk pathway in non-small cell lung cancer oncogenesis. BMC Cancer 2015; 15: 381.
30. Yang Z, Rayala S, Nguyen D, Vadlamudi RK, Chen S, Kumar R. Pak1 phosphorylation of snail, a master regulator of epithelial-to-mesenchyme transition, modulates snail’s subcellular localization and functions. Cancer Res 2005; 65: 3179–3184.
31. Zhang X, Mao H, Chen JY, Wen S, Li D, Ye M et al. Increased expression of microRNA-221 inhibits PAK1 in endothelial progenitor cells and impairs its function via c-Raf/MEK/ERK pathway. Biochem Biophys Res Commun 2013; 431: 404–408.
32. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013; 6: pl1.
33. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012; 2: 401–404.
34. Garber ME, Troyanskaya OG, Schluens K, Petersen S, Thaesler Z, Pacyna-Gengelbach M et al. Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci USA 2001; 98: 13784–13789.
35. Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, Misek DE et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002; 8: 816–824.